Consun Pharmaceutical Group Overview
- Year Founded
-
1997
- Status
-
Public
- Employees
-
3,108
- Stock Symbol
-
01681
- Investments
-
2
- Share Price
-
$0.64
- (As of Thursday Closing)
Consun Pharmaceutical Group General Information
Description
Consun Pharmaceutical Group Ltd is a biotechnology company with sales operations throughout China. Its principal activities are making and selling pharmaceutical products. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Consun derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
Contact Information
- 71, Dongpeng Avenue Eastern section
- Guangzhou Economic and Technological Development D
- Guangzhou, Guangdong 510760
- China
Consun Pharmaceutical Group Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.64 | $0.63 | $0.37 - $0.75 | $522M | 810M | 672K | $0.13 |
Consun Pharmaceutical Group Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 214,372 | 168,561 | 284,133 | 237,135 |
| Revenue | 354,536 | 347,411 | 316,654 | 253,717 |
| EBITDA | 110,315 | 116,009 | 114,991 | 93,947 |
| Net Income | 105,546 | 101,404 | 91,399 | 72,198 |
| Total Assets | 693,068 | 709,113 | 684,448 | 604,634 |
| Total Debt | 74,127 | 66,699 | 95,852 | 84,094 |
Consun Pharmaceutical Group Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Consun Pharmaceutical Group Executive Team (5)
Consun Pharmaceutical Group Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00 00000 | Consun Pharmaceutical Group | Co-Founder, Chairman & Executive Director | 000 0000 |
| 00 00000000 | Consun Pharmaceutical Group | Co-Founder, President & Vice Chairman | 000 0000 |
Consun Pharmaceutical Group Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Consun Pharmaceutical Group Investments & Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 00000 | 16-Aug-2016 | 000000000 | 000.00 | Drug Discovery | |
| Guangxi Yulin Pharmaceutical | 09-Nov-2015 | Merger/Acquisition | 00000 | Drug Discovery |
Consun Pharmaceutical Group Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| 0000000 00000 0000 | Drug Discovery | Yulin, China | 0000 |
Consun Pharmaceutical Group ESG
Risk Overview
Risk Rating
Updated December, 31, 2022
32.58 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,491
Rank
Percentile
Pharmaceuticals
Industry
00 of 871
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 415
Rank
Percentile
